All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 2022 ASCO Annual Meeting, the ALL Hub spoke with Bijal D. Shah, Moffit Cancer Center, Tampa, US. We asked for a ZUMA-3 trial update of brexucabtagene autoleucel in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).
ZUMA-3 trial update of brexucabtagene autoleucel in adult patients with R/R B-ALL
Shah shares data from the 2-year follow-up of the ZUMA-3 trial, discussing the long-term impact of allogeneic stem cell transplants. Shah outlines promising findings on overall survival for different patient groups and highlights a lack of trend in toxicity data.
Brexucabtagene autoleucel receives a positive opinion from EMA CHMP for the treatment of patients with R/R B-ALL
Given the high treatment burden and low-survival rate of patients with R/R B-ALL, approval of brexu-cel marks a positive treatment...
Supplemental biologics license application submitted for brexucabtagene autoleucel for use in R/R B-cell ALL
Relapsed or refractory (R/R) acute lymphoblastic lymphoma (ALL) is associated with poor prognosis and short overall survival. B-cell ALL is...
Subscribe to get the best content related to ALL delivered to your inbox